Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir : A multinational study
© 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd..
BACKGROUND AND AIM: The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)-related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear.
METHODS: A total of 2542 patients with CHB treated with either ETV or TDF were recruited from a multinational cohort. A 1:1 propensity score matching was performed to balance the differences in baseline characteristics between the two patient groups. We aimed to compare the all-cause, liver-related, and non-liver-related mortality between patients receiving ETV and those receiving TDF.
RESULTS: The annual incidence of all-cause mortality in the entire cohort was 1.0/100 person-years (follow-up, 15 757.5 person-years). Patients who received TDF were younger and had a higher body mass index, platelet count, hepatitis B virus deoxyribonucleic acid levels, and proportion of hepatitis B e-antigen seropositivity than those who received ETV. The factors associated with all-cause mortality were fibrosis-4 index > 6.5 (hazard ratio [HR]/confidence interval [CI]: 3.13/2.15-4.54, P < 0.001), age per year increase (HR/CI: 1.05/1.04-1.07, P < 0.001), alanine aminotransferase level per U/L increase (HR/CI: 0.997/0.996-0.999, P = 0.003), and γ-glutamyl transferase level per U/L increase (HR/CI: 1.002/1.001-1.003, P < 0.001). No significant difference in all-cause mortality was observed between the ETV and TDF groups (log-rank test, P = 0.69). After propensity score matching, no significant differences in all-cause, liver-related, or non-liver-related mortality were observed between the two groups.
CONCLUSIONS: Long-term outcomes of all-cause mortality and liver-related and non-liver-related mortality did not differ between patients treated with ETV and those receiving TDF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of gastroenterology and hepatology - (2024) vom: 13. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jang, Tyng-Yuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigen |
|---|
| Anmerkungen: |
Date Revised 13.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1111/jgh.16537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369697189 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369697189 | ||
| 003 | DE-627 | ||
| 005 | 20240315000313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jgh.16537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM369697189 | ||
| 035 | |a (NLM)38480009 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jang, Tyng-Yuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir |b A multinational study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a BACKGROUND AND AIM: The benefits of entecavir (ETV) versus tenofovir disoproxil fumarate (TDF) in reducing the development of chronic hepatitis B (CHB)-related hepatocellular carcinoma remain controversial. Whether mortality rates differ between patients with CHB treated with ETV and those treated with TDF is unclear | ||
| 520 | |a METHODS: A total of 2542 patients with CHB treated with either ETV or TDF were recruited from a multinational cohort. A 1:1 propensity score matching was performed to balance the differences in baseline characteristics between the two patient groups. We aimed to compare the all-cause, liver-related, and non-liver-related mortality between patients receiving ETV and those receiving TDF | ||
| 520 | |a RESULTS: The annual incidence of all-cause mortality in the entire cohort was 1.0/100 person-years (follow-up, 15 757.5 person-years). Patients who received TDF were younger and had a higher body mass index, platelet count, hepatitis B virus deoxyribonucleic acid levels, and proportion of hepatitis B e-antigen seropositivity than those who received ETV. The factors associated with all-cause mortality were fibrosis-4 index > 6.5 (hazard ratio [HR]/confidence interval [CI]: 3.13/2.15-4.54, P < 0.001), age per year increase (HR/CI: 1.05/1.04-1.07, P < 0.001), alanine aminotransferase level per U/L increase (HR/CI: 0.997/0.996-0.999, P = 0.003), and γ-glutamyl transferase level per U/L increase (HR/CI: 1.002/1.001-1.003, P < 0.001). No significant difference in all-cause mortality was observed between the ETV and TDF groups (log-rank test, P = 0.69). After propensity score matching, no significant differences in all-cause, liver-related, or non-liver-related mortality were observed between the two groups | ||
| 520 | |a CONCLUSIONS: Long-term outcomes of all-cause mortality and liver-related and non-liver-related mortality did not differ between patients treated with ETV and those receiving TDF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ETV | |
| 650 | 4 | |a NA | |
| 650 | 4 | |a TDF | |
| 650 | 4 | |a antigen | |
| 650 | 4 | |a antiviral | |
| 650 | 4 | |a cohort | |
| 650 | 4 | |a fibrosis | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a liver | |
| 650 | 4 | |a prognosis | |
| 700 | 1 | |a Liang, Po-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Jun, Dae Won |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Jang Han |e verfasserin |4 aut | |
| 700 | 1 | |a Toyoda, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chih-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Man-Fung |e verfasserin |4 aut | |
| 700 | 1 | |a Cheung, Ka Shing |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Sung Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Eileen L |e verfasserin |4 aut | |
| 700 | 1 | |a An, Jihyun |e verfasserin |4 aut | |
| 700 | 1 | |a Enomoto, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Kozuka, Ritsuzo |e verfasserin |4 aut | |
| 700 | 1 | |a Chuma, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Nozaki, Akito |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Tsunamasa |e verfasserin |4 aut | |
| 700 | 1 | |a Atsukawa, Masanori |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Taeang |e verfasserin |4 aut | |
| 700 | 1 | |a Hayama, Korenobu |e verfasserin |4 aut | |
| 700 | 1 | |a Ishigami, Masatoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Yong Kyun |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Eiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hyoung Su |e verfasserin |4 aut | |
| 700 | 1 | |a Shim, Jae-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Uojima, Haruki |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Soung Won |e verfasserin |4 aut | |
| 700 | 1 | |a Ahn, Sang Bong |e verfasserin |4 aut | |
| 700 | 1 | |a Takaguchi, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Senoh, Tomonori |e verfasserin |4 aut | |
| 700 | 1 | |a Buti, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas-Accarino I, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Kaori |e verfasserin |4 aut | |
| 700 | 1 | |a Yeh, Ming-Lun |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Chia-Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jee-Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chung-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Chuang, Wan-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Mindie H |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ming-Lung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of gastroenterology and hepatology |d 1989 |g (2024) vom: 13. März |w (DE-627)NLM012635235 |x 1440-1746 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:13 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jgh.16537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 13 |c 03 | ||